SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Jamie Thomas discussing results from the MAST trial assessing the validation of PAM50 for predicting progression in ...

Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in ...

A cohort study of over 40,000 patients suggests that levels should be monitored for at least three months — longer than commonly practiced ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor Prostate Specific Antigen (PSA) levels.

Investigators assess the impact of increasing persistent PSA levels on prostate cancer–specific mortality and all-cause ...

SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Arjun Pon Avudaiappan discussing survival outcomes of radical prostatectomy versus dose-escalated radiation with ADT ...

Japanese scientists, examining data from 20,000 people, found that men with low libido had a much higher risk of serious ...

Dear Dr. Roach: I am 90 years old. About 20 years ago, I had prostate cancer and went through 43 weeks of radiation. My PSA level in the past year has risen slightly from .03 ng/mL to .09 ng/mL. My ...

A 66-year-old male patient underwent surgery for prostate cancer 4 years ago. His initial prostate-specific antigen (PSA) ...

Prostate artery embolization (PAE) is a procedure that helps treat urinary symptoms of an enlarged prostate without a risk of sexual side effects. Typically, both Original Medicare (parts A and B ...